[go: up one dir, main page]

WO2001022969A3 - Vasopressin agonist formulation and process - Google Patents

Vasopressin agonist formulation and process Download PDF

Info

Publication number
WO2001022969A3
WO2001022969A3 PCT/US2000/026380 US0026380W WO0122969A3 WO 2001022969 A3 WO2001022969 A3 WO 2001022969A3 US 0026380 W US0026380 W US 0026380W WO 0122969 A3 WO0122969 A3 WO 0122969A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
vasopressin agonist
agonist formulation
formulations
vasopressin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/026380
Other languages
French (fr)
Other versions
WO2001022969A2 (en
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to MXPA02003191A priority Critical patent/MXPA02003191A/en
Priority to CA002385971A priority patent/CA2385971A1/en
Priority to EP00965432A priority patent/EP1216045A2/en
Priority to AU76152/00A priority patent/AU7615200A/en
Priority to JP2001526180A priority patent/JP2003510280A/en
Publication of WO2001022969A2 publication Critical patent/WO2001022969A2/en
Publication of WO2001022969A3 publication Critical patent/WO2001022969A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having general structure (I), and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.
PCT/US2000/026380 1999-09-27 2000-09-26 Vasopressin agonist formulation and process Ceased WO2001022969A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA02003191A MXPA02003191A (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process.
CA002385971A CA2385971A1 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process
EP00965432A EP1216045A2 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process
AU76152/00A AU7615200A (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process
JP2001526180A JP2003510280A (en) 1999-09-27 2000-09-26 Vasopressin agonist prescription and manufacturing method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40616599A 1999-09-27 1999-09-27
US09/406,165 1999-09-27

Publications (2)

Publication Number Publication Date
WO2001022969A2 WO2001022969A2 (en) 2001-04-05
WO2001022969A3 true WO2001022969A3 (en) 2001-12-20

Family

ID=23606805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026380 Ceased WO2001022969A2 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process

Country Status (7)

Country Link
EP (1) EP1216045A2 (en)
JP (1) JP2003510280A (en)
CN (1) CN1391476A (en)
AU (1) AU7615200A (en)
CA (1) CA2385971A1 (en)
MX (1) MXPA02003191A (en)
WO (1) WO2001022969A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
ATE482747T1 (en) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
WO1996022293A1 (en) * 1995-01-17 1996-07-25 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1999006409A1 (en) * 1997-07-30 1999-02-11 American Home Products Corporation Tricyclic vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
WO2000046227A1 (en) * 1999-02-04 2000-08-10 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
WO1996022293A1 (en) * 1995-01-17 1996-07-25 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1999006409A1 (en) * 1997-07-30 1999-02-11 American Home Products Corporation Tricyclic vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
WO2000046227A1 (en) * 1999-02-04 2000-08-10 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1216045A2 *

Also Published As

Publication number Publication date
AU7615200A (en) 2001-04-30
MXPA02003191A (en) 2002-09-30
CN1391476A (en) 2003-01-15
CA2385971A1 (en) 2001-04-05
EP1216045A2 (en) 2002-06-26
JP2003510280A (en) 2003-03-18
WO2001022969A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
CA2158630A1 (en) Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
AU3038197A (en) Aerosol formulations
CA2448035A1 (en) New pharmaceutical composition
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2001005355A3 (en) Formulations for il-11
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2001005388A3 (en) Use of a fatty derivative for the treatment of external secretiondisorders
AU2093101A (en) Compositions for efficient release of active ingredients
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
CA2294033A1 (en) Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
HK1052872A1 (en) Micelles
HUP0204513A3 (en) Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
WO2001093816A3 (en) Stabilized compositions containing oxygen-labile active agents
EP1600441A3 (en) Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
WO2001022969A3 (en) Vasopressin agonist formulation and process
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
AU2001215584A1 (en) A pharmaceutical composition having chlorogenic acid as active component for preventing or treating the declining of male reproduction capability
HK1044485A1 (en) Pharmaceutical carrier formulation
AU2421601A (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
HK1045109A1 (en) Vasopressin antagonist formulation and process
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
MXPA01004457A (en) Novel pyrimidine derivatives and processes for the preparation thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965432

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526180

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2385971

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003191

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008160090

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000965432

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000965432

Country of ref document: EP